Latest News and Press Releases
Want to stay updated on the latest news?
-
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...
-
Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
-
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
-
Inozyme announced that it will host a conference call and webcast on Monday, Apr. 8, 2024 at 8:00 a.m. ET.
-
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...
-
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency – – Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment...
-
BOSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal...